Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVI NASDAQ:CING NASDAQ:GLTO NASDAQ:MRKR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$7.10+1.5%$10.16$6.20▼$75.00$13.20M0.7351,339 shs37,020 shsCINGCingulate$4.69+3.8%$4.15$1.80▼$20.83$19.89M-0.791.10 million shs86,998 shsGLTOGalecto$3.77+6.1%$3.22$2.01▼$15.14$4.97M1.35137,801 shs27,396 shsMRKRMarker Therapeutics$1.56-0.6%$1.43$0.95▼$5.99$17.65M1.43118,488 shs25,402 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie+5.59%-17.47%-38.68%-11.88%+60.32%CINGCingulate-4.44%+0.22%+7.62%+8.13%+1,032.83%GLTOGalecto-8.97%+6.93%+5.97%+49.16%-75.97%MRKRMarker Therapeutics-0.63%-1.88%-1.88%+45.37%-71.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie1.0605 of 5 stars0.04.00.00.03.60.00.6CINGCingulate3.2878 of 5 stars3.55.00.00.02.61.70.6GLTOGalecto3.2181 of 5 stars3.55.00.00.01.11.71.3MRKRMarker Therapeutics4.4788 of 5 stars3.85.00.03.92.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 4.00Strong BuyN/AN/ACINGCingulate 3.00Buy$26.00453.90% UpsideGLTOGalecto 3.00Buy$10.00165.60% UpsideMRKRMarker Therapeutics 3.50Strong Buy$13.17744.02% UpsideCurrent Analyst Ratings BreakdownLatest GLTO, CING, MRKR, and BIVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $61.005/19/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$12.00 ➝ $11.004/21/2025CINGCingulateAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $60.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$25.35 per shareN/ACINGCingulateN/AN/AN/AN/A$2.32 per shareN/AGLTOGalectoN/AN/AN/AN/A$10.99 per shareN/AMRKRMarker Therapeutics$6.59M2.68N/AN/A$1.73 per share0.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$32.12M-$79.10N/A∞N/AN/A-100.88%-78.49%8/21/2025 (Estimated)CINGCingulate-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%8/12/2025 (Estimated)GLTOGalecto-$21.44M-$15.53N/AN/AN/AN/A-98.27%-84.29%8/11/2025 (Estimated)MRKRMarker Therapeutics-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)Latest GLTO, CING, MRKR, and BIVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025MRKRMarker Therapeutics-$0.55N/AN/AN/A$0.72 millionN/A8/12/2025Q2 2025CINGCingulate-$0.82N/AN/AN/AN/AN/A5/12/2025Q3 2025BIVIBioVie-$3.20-$1.50+$1.70-$0.15N/AN/A5/8/2025Q1 2025CINGCingulate-$1.00-$1.04-$0.04-$1.04N/AN/A5/8/2025Q1 2025GLTOGalectoN/A-$1.92N/A-$1.92N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AGLTOGalectoN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A9.319.31CINGCingulate0.161.871.87GLTOGalectoN/A9.629.62MRKRMarker TherapeuticsN/A6.796.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%CINGCingulate41.31%GLTOGalecto14.20%MRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipBIVIBioVie2.39%CINGCingulate17.06%GLTOGalecto10.80%MRKRMarker Therapeutics14.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie101.86 million1.81 millionNo DataCINGCingulate204.25 million3.52 millionNot OptionableGLTOGalecto401.32 million1.18 millionOptionableMRKRMarker Therapeutics6011.32 million9.67 millionNot OptionableGLTO, CING, MRKR, and BIVI HeadlinesRecent News About These CompaniesHere's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn SituationJuly 11, 2025 | finance.yahoo.comMarker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with LymphomaJune 17, 2025 | globenewswire.comMarker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with LymphomaMay 20, 2025 | globenewswire.comMarker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell TherapiesMay 19, 2025 | globenewswire.comArkansas Historic Preservation Program hosts National Historic Marker WeekendApril 17, 2025 | stuttgartdailyleader.comSMarker Therapeutics (MRKR) Receives a Buy from Canaccord GenuityApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology ConferenceApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology ConferenceApril 1, 2025 | globenewswire.comMarker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last yearMarch 31, 2025 | markets.businessinsider.comMarker Therapeutics Reports Year-End 2024 Corporate and Financial ResultsMarch 31, 2025 | globenewswire.comMarker Therapeutics stockholder vote clears warrant issuanceMarch 28, 2025 | investing.comMarker Therapeutics initiated with a Buy at CanaccordMarch 5, 2025 | markets.businessinsider.comCanaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy RecommendationMarch 5, 2025 | msn.comMarker Therapeutics, Inc. CEO Juan Vera to Present at H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceFebruary 25, 2025 | quiverquant.comQMarker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceFebruary 25, 2025 | globenewswire.comMRKR stock touches 52-week low at $1.61 amid market challengesFebruary 12, 2025 | msn.comBrookline Capital sets $4 target on Marker Therapeutics stockFebruary 11, 2025 | msn.comMarker Therapeutics initiated with a Buy at BrooklineFebruary 11, 2025 | markets.businessinsider.comMRKR stock touches 52-week low at $1.8 amid market challengesJanuary 31, 2025 | msn.comMarker Therapeutics Announces Board ResignationJanuary 31, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffUPS Is Outpacing the Market: A Green Light for Investors?By Jeffrey Neal Johnson | June 27, 2025View UPS Is Outpacing the Market: A Green Light for Investors?Datadog Joins S&P 500, Triggering a New Wave of UpsideBy Gabriel Osorio-Mazilli | July 7, 2025View Datadog Joins S&P 500, Triggering a New Wave of UpsideGLTO, CING, MRKR, and BIVI Company DescriptionsBioVie NASDAQ:BIVI$7.10 +0.11 (+1.50%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Cingulate NASDAQ:CING$4.69 +0.17 (+3.85%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Galecto NASDAQ:GLTO$3.76 +0.22 (+6.06%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Marker Therapeutics NASDAQ:MRKR$1.56 -0.01 (-0.64%) As of 02:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
